HONG KONG – As the incidence of diabetes in China continues to climb to alarming rates, multinational and local pharmaceutical companies are racing to take a larger slice of the growing market pie, but patients in lower-tier cities will have to wait before they can access innovative treatments.
When the FDA recently gave drug manufacturers a one-year grace period on complying with the Nov. 27 serialization requirements of the Drug Supply Chain Security Act (DSCSA), a lot of companies likely heaved a sigh of relief.
Comparative sequencing of primary breast tumors and metastases has revealed that the cells that seed metastases break off from the primary tumor relatively late in tumor development, and as a result, are usually genetically similar to the primary tumor at the time of diagnosis.
Dynavax Technologies Corp. raised net proceeds of about $64.5 million through a public offering of 27.6 million shares of its common stock, including 3.6 million shares sold to its underwriters.
Achieve Life Sciences Inc., of Bothell, Wash., said it initiated the development program for its smoking cessation candidate, cytisine, a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor that is approved and marketed in Central and Eastern Europe.
A combination of the Bristol-Myers Squibb Co. checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) diminished the size of previously untreated renal cell carcinomas (RCC) for more people than Pfizer Inc.'s Sutent (sunitinib) during a closely watched phase III trial.
Responding to the U.S. Trade Representative (USTR) promise to make investigating China's trade policies one of its highest priorities, China sent the USTR a bit of a warning Tuesday.
Cymabay Therapeutics Inc., of Newark, Calif., said the proof-of-concept study of seladelpar, a peroxisome proliferator-activated receptor delta agonist, for the treatment of primary biliary cholangitis (PBC) was published by Lancet Gastroenterology and Hepatology, a peer-reviewed journal. The research was published as a collaboration involving key international PBC experts.
Aradigm Corp., of Hayward, Calif., said it was awarded a two-year phase II small business innovation research (SBIR) grant of approximately $972,000 by the National Institute of Allergy and Infectious Diseases and NIH to investigate the treatment of the pulmonary non-tuberculous mycobacteria (PNTM) infections, Mycobacterium avium and Mycobacterium abscessus, with its inhaled liposomal ciprofloxacin products, Linhaliq (formerly Pulmaquin) and Lipoquin.
RSS